FDA Establishes Class II Classification for TENS Devices Intended to Reduce Fibromyalgia Symptoms

The U.S. Food and Drug Administration (FDA) has issued a final order classifying transcutaneous electrical nerve stimulators (TENS) intended to reduce fibromyalgia symptoms as Class II medical devices with special controls.

The decision codifies a classification order originally granted through the De Novo pathway for the Quell-FM device developed by NeuroMetrix, Inc. The final order became effective on 29 May 2026 and establishes a new device type under 21 CFR 882.5888.

According to the FDA, the device is defined as a prescription device that transcutaneously stimulates a patient's sensory nerves through electrodes placed on the skin to treat fibromyalgia symptoms.

Special Controls Established

To provide reasonable assurance of safety and effectiveness, the FDA has established a set of special controls that apply to this device type.

Manufacturers must demonstrate:

• Non-clinical performance testing under anticipated conditions of use;

• Characterisation of electrical stimulation parameters, including waveform, output modes, voltage, current, pulse duration and frequency;

• Characterisation of the impedance monitoring system;

• Characterisation of electrode performance, including electrical performance, adhesive integrity, shelf life, reusability and current distribution;

• Biocompatibility of patient-contacting components;

• Electrical, thermal and mechanical safety;

• Electromagnetic compatibility (EMC);

• Software verification, validation and hazard analysis; and

• Specific labelling requirements covering treatment regimens, electrode shelf life, technical specifications and instructions for use.

The FDA identified several risks associated with the device type, including adverse tissue reactions, skin discomfort, burns, electrical shock, device interference and delayed or ineffective treatment due to user error. The agency concluded that these risks can be adequately mitigated through the combination of general controls and the newly established special controls.

What This Means for Manufacturers

The new classification creates a dedicated regulatory pathway for TENS devices intended to reduce fibromyalgia symptoms.

Importantly, the classification establishes a new Class II device type that may serve as a predicate for future devices. Manufacturers developing substantially equivalent products may be able to pursue the 510(k) pathway rather than submitting a De Novo request, subject to applicable FDA requirements.

Companies active in neuromodulation, pain management and electrostimulation technologies should review the new special controls and assess whether their design verification, validation, software documentation, performance testing and labelling activities align with the FDA's expectations for this device category.

The final rule formally adds §882.5888, "Transcutaneous Electrical Nerve Stimulator to Treat Fibromyalgia Symptoms," to the neurological devices regulations under 21 CFR Part 882.